Brought to you by 
Danaher acquires GE Life Sciences' biopharma business for $21.4bn
18 Sep 2019
Executive Summary
Danaher Corp. agreed to acquire the biopharma business (instruments, consumables, and software supporting research, discovery, process development, and manufacturing workflows of biopharmaceutical drugs, vaccines, and cell therapies) of GE Healthcare's GE Healthcare Life Sciences division for $21.4bn ($21bn in cash and $400mm for the assumption of pension liabilities), or about 17 times the biopharma unit's expected 2019 EBITDA.
Deal Industry
- Contract Research, Toxicology Testing-CRO
- Research, Analytical Equipment & Supplies
- Services
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Gene Therapy, Cell Therapy
- Synthesis Technologies, Production Processes
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Danaher acquires GE Life Sciences' biopharma business for $21.4bn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice